Skip to content
Radio Logo
PodcastsLife SciencesSmart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders

David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist
Latest episode

307 episodes

  • Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders

    306: Over 90% Antibody Galactosylation Through Cell Line Engineering Alone: Built In Before Scale-Up with Ioscani Jiménez del Val and Gertjan Bartlema - Part 2

    2026/11/19 | 19 mins.
    Most academic breakthroughs in glycoengineering never make it past the lab bench—not because the science isn’t solid, but because translating innovation into the clinic demands more than technical excellence.
    That journey was at the heart of the conversation with Dr. Ioscani Jiménez del Val (CSO) and Gertjan Bartlema (CEO) of Glyvantis Bio on the Smart Biotech Scientist Podcast. Together, they explore how academic discoveries can translate into industrial applications—and why getting the commercial and cultural transition right is essential.
    Topics discussed:
    Navigating the mindset shift from academia to commercial biotech—including leveraging tech transfer offices and institutional support (02:32)
    Lessons from pairing operational/commercial leadership with scientific founders, and the benefits of cross-disciplinary collaboration (04:21)
    Key challenges in turning top-tier academic technology into a fundable and credible company (06:24)
    The importance and mechanics of building industrial-scale data packages to validate new biotech platforms (07:52)
    Balancing the dual identity of a tools company and a therapeutics developer, and how parallel strategies can work (09:35)
    Practical advice for academics considering entrepreneurship, including the value of humility and moving quickly (11:32)
    Reflections on what could be done differently in the commercialization process (13:44)
    Broader concerns about early-stage science funding in Europe versus the US, and the need to support emerging research (14:33)
    Final takeaways on why people and teams are ultimately the driving force behind technological progress (15:47)
    Smart insight: The journey from academic bench to clinical impact is as much about people as it is about science. The most important takeaways from the conversation: build strong, passionate teams; be willing to embrace new mindsets and continuous learning; and don’t be afraid to act. For the biotech scientist, stepping out of the comfort zone and into the world of entrepreneurship may be challenging, but the rewards—for patients and for personal growth—can be transformative.
    If this conversation got you thinking about your own glycosylation strategy, here are a few episodes to listen to next:
    Episodes 227 - 228: Media-Based Glycan Engineering for Biosimilars
    Episodes 43 - 44: Mastering the Art and Science of Glycan Engineering in Drug Development with Henning von Horsten
    Episodes 69 - 70: Glycoanalytics Explained: Analysing and Designing Better Biopharmaceutical Drugs with Róisín O’Flaherty
    Episodes 17 - 18: How Extracting Gold From Your Data Accelerates Process Development with Ioscani Jiménez del Val
    Connect with Ioscani Jiménez del Val and Gertjan Bartlema
    Website: www.glyvantisbio.com
    LinkedIn Ioscani Jiménez del Val: www.linkedin.com/in/ioscanij
    LinkedIn Gertjan Bartlema: www.linkedin.com/in/gertjan-bartlema
    Support the show
  • Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders

    305: Over 90% Antibody Galactosylation Through Cell Line Engineering Alone: Built In Before Scale-Up with Ioscani Jiménez del Val and Gertjan Bartlema - Part 1

    2026/11/17 | 22 mins.
    Glycosylation, as a critical quality attribute, remains one of the most challenging variables to control in the production and optimization of therapeutic proteins. Even minor fluctuations in glycan profiles can make or break a promising antibody, impacting quality, efficacy, and commercial viability.
    Ioscani Jiménez del Val, Associate Professor at University College Dublin and scientific co-founder of Glyvantis Bio, has joined forces with biotech leader Gertjan Bartlema to launch the company and introduce Galixa™, a glycoengineering platform designed to give developers greater control over antibody galactosylation.
    Topics discussed:
    Personal journeys into biotech and what sparked long-term passion for the field (04:04)
    The team dynamic and motivation to bring promising scientific advancements out of academia and into real-world application (05:32)
    Why glycosylation is a critical quality attribute and so difficult to control in therapeutic proteins (07:41)
    The commercial perspective on current industry solutions versus a proactive, root-cause approach to glycosylation control (09:49)
    How the Galixa technology works, including details on cell line engineering and addressing metabolic and cellular bottlenecks (13:14)
    The role of computational modeling (ChompAct) in identifying and validating engineering targets (15:45)
    The importance of reliable and robust data as a catalyst for industry adoption and next steps in scaling up new bioprocessing technologies (17:39)
    Application of the technology to more complex biologics such as bispecifics and those with highly branched glycans, as well as potential limitations (18:36)
    Smart insight: Most biomanufacturers patch glycosylation variability late in development, often with media tweaks. Glyvantis Bio’s approach starts earlier, at cell line development. It engineers CHO cells to deliver robust, highly consistent N-glycan galactosylation, opening the door to tighter specifications and better antibodies.
    If this conversation got you thinking about your own glycosylation strategy, here are a few episodes to listen to next:
    Episodes 227 - 228: Media-Based Glycan Engineering for Biosimilars
    Episodes 43 - 44: Mastering the Art and Science of Glycan Engineering in Drug Development with Henning von Horsten
    Episodes 69 - 70: Glycoanalytics Explained: Analysing and Designing Better Biopharmaceutical Drugs with Róisín O’Flaherty
    Episodes 17 - 18: How Extracting Gold From Your Data Accelerates Process Development with Ioscani Jiménez del Val
    Connect with Ioscani Jiménez del Val and Gertjan Bartlema
    Website: www.glyvantisbio.com
    LinkedIn Ioscani Jiménez del Val: www.linkedin.com/in/ioscanij
    LinkedIn Gertjan Bartlema: www.linkedin.com/in/gertjan-bartlema
    Support the show
  • Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders

    304: From Freezer to Bedside: Controlling Cryopreservation Variability in Cell Therapy Manufacturing with Sean Werner - Part 2

    2026/11/12 | 17 mins.
    Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances? Biopreservation and cell processing are critical pain points in scaling advanced therapies for global distribution, with variables like cryoprotectant toxicity, transport stability, and automation dictating both cost and clinical success.
    Sean Werner, CTO of Cell Processing at BioLife Solutions and former Sexton Biotechnologies leader, has seen the real cost when assumptions break down at scale. From container fractures to uncertain analytics, he’s guided teams through the frontline challenges of CMC and biologics.
    Topics discussed:
    Why decentralized manufacturing and local storage might be the most practical path forward for delivering cell therapies globally (03:05)
    Key distribution chain challenges—how logistics complexity escalates with cross-border shipments and the risks of primary packaging failure (03:44)
    Regulatory expectations for transport validation and the importance of container integrity during shipping (04:49)
    The growing role of automation and closed systems in reducing manual steps, with a look at current capabilities and future directions (06:41)
    How more advanced analytics could unlock greater efficiencies and reduce manufacturing costs in cell therapy (07:49)
    Practical guidance for scientists looking to optimize freezing and thawing processes, including common assumptions to avoid (08:39)
    When it makes sense to use DMSO, risk management considerations, and whether DMSO-free really means safer (10:39)
    Long-term aspirations for room-temperature biopreservation and challenging industry assumptions about stability (13:13)
    The importance of process control and attention to detail in minimizing variability and improving clinical outcomes (14:44)
    Smart insight: Sean Werner challenged the field to move beyond the cryo status quo: can we develop technologies for stable room temperature storage of living cells and biologics? While the hurdles are immense, questioning established dogma is the only route to transformative change. Above all, he warned, never treat biopreservation as an afterthought—the variability it introduces can undermine even the most promising therapies . As cell therapy matures, early and continual investment in process innovation and discipline will remain key.
    If this episode has you rethinking freeze-thaw, here’s where to go next. Start with the science behind cryopreservation, then compare two takes on cryoprotectants: DMSO-free formulations and antifreeze-inspired chemistry.
    Episodes 241 - 242: DMSO in Cell Therapy: Why Viability Scores Hide the Real Toxicity with Steve Oh
    Episodes 161 - 162: How to Achieve 85%+ Cell Recovery Without DMSO’s Toxic Side Effects with Jeffrey Allen
    Episodes 65 - 66: Freezing and Thawing Cells: the Science Behind Cryopreservation with Mark Davison
    Episodes 129 - 130: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster
    Connect with Sean Werner:
     Website: www.biolifesolutions.com
    LinkedIn: https://www.linkedin.com/in/sean-werner-54688326/
    Support the show
  • Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders

    303: From Freezer to Bedside: Controlling Cryopreservation Variability in Cell Therapy Manufacturing with Sean Werner - Part 1

    2026/11/10 | 21 mins.
    The integrity of individual cells is the cornerstone of breakthrough cell and gene therapies—but translating lab discoveries into clinical success demands mastering cryopreservation challenges rarely discussed in depth.
    Sean Werner, Chief Technology Officer of Cell Processing at BioLife Solutions,a leading provider of bioproduction tools and services to the cell and gene therapy and broader biopharma markets, has dedicated his career to safeguarding cell viability from the lab bench through to clinical application.
    Topics discussed:
    Sean Werner's unconventional career progression and early experiences in regenerative medicine (03:22)
    The critical role of cryopreservation in cell and gene therapy product quality (05:59)
    Biophysics of freezing: ice nucleation, supercooling, and their impact on cell viability (07:32)
    Hidden pitfalls in cryopreservation, including ice recrystallization and osmotic stress (07:43)
    Real-world challenges during clinical handling and thawing of cell therapies (11:18)
    Why the commonly used -1°C per minute freeze rate is not universally optimal (13:09)
    Difficulties in tracing clinical problems back to early cryopreservation choices (13:54)
    Importance of evaluating long-term cell function, not just post-thaw viability (15:08)
    Regulatory expectations around freeze-thaw processes in therapy manufacturing (16:34)
    Smart insight: Success in cell therapy and advanced biologics is inseparable from mastery of cryopreservation. By adopting an experimental and data-driven mindset—questioning assumptions, customizing protocols, and measuring what truly matters—scientists can better fulfill that original promise: that a single cell, carefully protected, can change the course of medicine for patients worldwide.
    If this episode has you rethinking freeze-thaw, here’s where to go next. Start with the science behind cryopreservation, then compare two takes on cryoprotectants: DMSO-free formulations and antifreeze-inspired chemistry.
    Episodes 241 - 242: DMSO in Cell Therapy: Why Viability Scores Hide the Real Toxicity with Steve Oh
    Episodes 161 - 162: How to Achieve 85%+ Cell Recovery Without DMSO’s Toxic Side Effects with Jeffrey Allen
    Episodes 65 - 66: Freezing and Thawing Cells: the Science Behind Cryopreservation with Mark Davison
    Episodes 129 - 130: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster
    Connect with Sean Werner:
     Website: www.biolifesolutions.com
    LinkedIn: https://www.linkedin.com/in/sean-werner-54688326/
    Support the show
  • Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders

    302: Why Rushing Cell Line Development Costs You Months Later: The Analytics-First CMC Strategy with Lars Stöckl and Lena Tholen - Part 2

    2026/11/05 | 21 mins.
    Biologics development is full of hidden pitfalls, from selecting the right cell line to navigating analytical assessments that can make or break a therapy's success.
    Today, we feature Lars Stöckl and Lena Tholen, industry experts from FyoniBio GmbH, who have deep experience guiding biotech teams through the maze of CMC development, troubleshooting both common and unusual product quality challenges.
    Topics discussed:
    Key factors in selecting host cell lines and the importance of matching the platform to molecule complexity (02:34)
    The role of broad analytical assays early in cell line and pool development for better decision-making (03:34)
    Glycosylation, post-translational modifications, and analytical strategies for both standard antibodies and more complex biotherapeutics (05:10)
    When and how to conduct developability and manufacturability assessments, especially for novel or specialized molecules (06:55)
    Troubleshooting glycosylation and aggregation problems—when to tweak the process and when to reconsider the molecule (08:05)
    Importance of clear, direct communication with clients regarding manufacturability and process viability (09:32)
    Example of how different CHO cell lines can dramatically impact molecule outcome and company trajectory (12:08)
    Keeping pace with technological advances through collaboration, conferences, and feasibility studies with startups (13:55)
    The move toward customization over standardization in cell line and process development (18:07)
    Smart insight: The future of bioprocess development lies in a customized, molecule-centric approach. Rather than relying on generic, pre-set development platforms, success comes from carefully matching cell lines, processes, and analytical methods to the unique requirements of each molecule. True innovation and commercial success arise from adapting everything—cell line, process, analytics—to the molecule at hand.
    Lars and Lena’s main point is that early choices about the host cell line, the analytics and the partner decide what’s possible later on. The episodes below take that idea further. One looks at the mechanics of cell line development, one at why promising molecules fail to manufacture, and two at outsourcing CMC work from the sponsor’s side.
    Episodes 117 - 118: Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea Gough
    Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein
    Episodes 103 - 104: One-Stop Shop vs. Specialist CDMO: A Scientist’s Guide to CDMO Selection with Sigma Mostafa
    Episodes 71 - 72: Effective Outsourcing: How Small Biotech Companies Can Thrive with Mark Melville
    Connect with Lars Stöckl and Lena Tholen:
     Website: www.fyonibio.com
    LinkedIn:www.linkedin.com/in/dr-lars-stoeckl
    LinkedIn: www.linkedin.com/in/lena-tholen-80642a11a
    Support the show
More Life Sciences podcasts
About Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders
The go-to CMC and biomanufacturing podcast for bioprocess development scientists and CMC leaders scaling biologics into regulatory-ready therapies with less trial and error.Practical, execution-focused, and strategic guidance on CMC development, tech transfer, scale-up, GMP readiness, CDMO partnerships, and manufacturing economics for biologics, cell and gene therapies, cultivated meat, and biomaterials.Hosted by Dr. David Brühlmann, CMC strategist, former Bioprocess Innovation Manager at Merck, PhD in glycoengineering, and close to 20 years of biomanufacturing experience. Smart Biotech Scientist delivers actionable insights for the people doing the hard work of turning promising molecules into scalable, regulatory-ready therapies.This podcast is for you if:You are a process development scientist or CMC lead managing a technology transfer, scale-up, or CDMO partnershipYou are a biologics developer working on upstream or downstream process development, cell culture optimization, or GMP manufacturing readinessYou are a biotech founder preparing for an IND filing or Series A fundraise, and need a CMC strategy that holds up under investor and regulatory scrutinyYou are building or advising an early-stage biopharma team and need to make smart manufacturing decisions with limited resourcesWhat you will learn:CMC strategy and regulatory planning, bioprocess scale-up from lab to clinical and commercial manufacturing, cell culture process development and media optimization, technology transfer best practices, CDMO selection and partnership management, hybrid modeling, manufacturing economics, continuous manufacturing, digitization, and Industry 4.0 in biopharma.Top 10 life sciences podcast with 200+ episodes and guests from Merck, FUJIFILM Irvine Scientific, Cytiva, KBI Biopharma, Eppendorf, and biotech innovators worldwide.New episodes released weekly. Subscribe and join 400+ biotech leaders already using these insights to accelerate development, reduce manufacturing costs, and de-risk scale-up.Next Steps:Get the 5-day CMC email course: https://smartbiotechscientist.com/#cmcVisit the website: https://smartbiotechscientist.comEmail us: hello@bruehlmann-consulting.com
Podcast website

Listen to Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders, The Naked Scientists Podcast and many other podcasts from around the world with the radio.net app

Get the free radio.net app

  • Stations and podcasts to bookmark
  • Stream via Wi-Fi or Bluetooth
  • Supports Carplay & Android Auto
  • Many other app features